Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingjin lavage solution is a Traditional Chinese Medicine (TCM) hospital preparation developed by the First Affiliated Hospital of Henan University of Chinese Medicine for the treatment of COVID-19. It received emergency approval from the Henan Provincial Medical Products Administration during the pandemic to address respiratory symptoms associated with SARS-CoV-2 infection. The formulation is designed to clear heat, detoxify the lungs, and resolve phlegm, specifically targeting the "lung-heat" syndrome common in viral pneumonia. In clinical practice, it has been utilized both as an oral medication and as a lavage fluid for bronchoalveolar lavage (BAL) in severe cases to help clear inflammatory secretions and mitigate the cytokine storm. The preparation is officially included in the Henan Province COVID-19 Diagnosis and Treatment Protocol.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qingjin lavage solution.